DDInter1615 DDInter1435
Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration. Neurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR). By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Rolapitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Rolapitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dextromethorphan
Rolapitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Rolapitant {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Rolapitant {u} may lead to a major life threatening interaction when taken with {v} Betrixaban
Rolapitant may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan
Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Rolapitant may lead to a major life threatening interaction when taken with Enzalutamide
Rolapitant may lead to a major life threatening interaction when taken with Betrixaban